TJP1

Across TCGA pan-cancer cohorts, TJP1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of TJP1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TJP1 RNA is repressed in tumor relative to normal tissue. In most cancer types TJP1 is over-expressed in tumor, although a few such as LUAD and KICH show the opposite, repressed pattern.

LUAD, LIHC, and KICH are the cancer types where TJP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TJP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.904	<.001	7	view →
LIHC	Female	II,III,IV	+0.898	<.001	7	view →
KICH	All	All	−0.883	<.001	7	view →
LUSC	Female	All	−1.197	<.001	6	view →
BRCA	All	III,IV	−0.563	<.001	6	view →
KIRC	All	II,III,IV	−0.400	.002	6	view →
CHOL	Male	All	+1.726	<.001	5	view →
UCEC	All	All	−1.102	<.001	2	view →
READ	Female	All	−0.969	.008	2	view →
PRAD	All	All	+0.507	<.001	2	view →
KIRP	Male	All	−0.349	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

TJP1–LUAD

Open the LUAD breakdown →